Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2023-06-20 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2022 annual equity distribution (dividend and stock bonus) by Hangzhou Anxu Biotechnology Co., Ltd. It details the dividend per share, stock bonus ratio, relevant dates, shareholder meeting approval, tax treatment, and share capital changes. The document is relatively short (2990 characters) and focuses on dividend distribution details rather than presenting full financial statements or comprehensive annual report content. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related shareholder information.
2023-06-20 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司2022年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导工作现场检查报告" which translates to "2022 Annual Continuous Supervision On-site Inspection Report" by the sponsoring institution (保荐机构) for a company listed on the STAR Market. The content details the scope and findings of an on-site inspection related to corporate governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, guarantees, major investments, and business operations during the 2022 continuous supervision period. It is a detailed report on regulatory compliance and operational checks conducted by the sponsor, not a full annual report or financial statement. It is not an announcement or a brief notice but a substantive report on the sponsor's supervisory activities. This fits the definition of an Audit Report / Information (AR), which includes standalone audit or inspection reports and regulatory compliance checks excluding full annual reports. The document length (2574 characters) is relatively short but contains detailed findings and opinions, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2022
2023-06-05 Chinese
信永中和会计师事务所关于安旭生物2022 年年度报告的信息披露监管问询函的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from the auditing firm ShineWing to the Shanghai Stock Exchange regarding inquiries about the 2022 annual report of Hangzhou Anxu Biotechnology Co., Ltd. It contains extensive financial data, analysis of revenue, gross margin, customer and supplier concentration, and risk disclosures related to the 2022 fiscal year and the first quarter of 2023. The document includes auditor's verification procedures and conclusions on the company's financial performance and risks. The presence of detailed financial figures, management discussion, and auditor's opinions related to the annual report indicates this is an Audit Report / Information document rather than the full Annual Report itself. It is not a brief announcement or a certification letter but a substantive audit response document. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2022
2023-06-01 Chinese
民生证券关于安旭生物2022年年报问询函回复的核查意见
Regulatory Filings
2023-06-01 Chinese
安旭生物关于对上海证券交易所2022年年度报告问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed response from Hangzhou Anxu Biotechnology Co., Ltd. to an inquiry letter from the Shanghai Stock Exchange regarding the company's 2022 annual report. It contains extensive financial data, analysis of revenue, gross profit margins, customer and supplier concentration, cost structure, and risk disclosures related to the 2022 fiscal year and the first quarter of 2023. The document addresses specific questions about the annual report's content, including management's explanations and supplementary disclosures. It is not the annual report itself but a regulatory inquiry response related to the annual report. Given the detailed financial and operational discussion, it is not a simple announcement or certification but a regulatory filing responding to a regulatory inquiry. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-06-01 Chinese
上海锦天城（杭州）律师事务所关于安旭生物2022年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Hangzhou Anxu Biotechnology Co., Ltd. It details the legality and validity of the AGM's convening, attendance, agenda, and voting results. The document includes specific voting outcomes on various proposals discussed at the AGM. It does not contain the full annual report or financial statements but rather focuses on the AGM procedures and resolutions. This type of document is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results from the AGM.
2023-05-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.